From earning point of view, the current PE is good, you can say ACR is cheap at under a dollar if, and only if , the sales will go up from here or at least stay at this level.
But the problem is: it is unclear if the lower sale is only a dip for this quarter, or some serious problem ahead.
What if the sales drops further next quarter?
What if Axiron lose market share to below 10%?
What if (rumored last year remember?)Lilly decides to drop Axiron or reduce the effort?
As I said the issue at the moment is not how much loyalty ACR gets from Lilly, it is why and how the sales are so low this quarter.
ACR management is obligated to explain to the market, but we are not seeing it.
ACR Price at posting:
69.0¢ Sentiment: Hold Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)